Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.04 +0.16 (+1.15%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
From Mirum Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for... 
Via Benzinga
Analyzing Takeda Pharmaceutical's Unusual Options Activity
Shares of Takeda Pharmaceutical (NYSE:TAK) saw some unusual ... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
ADHD Drug Developer Cingulate Plans NASDAQ Debut
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention... 
Via Benzinga
Topics Initial Public Offering
Why Novavax Stock Is Slipping Again Today
A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock. 
Via The Motley Fool
Why Novavax Stock Surged Today
The biotech's coronavirus-related revenue could be about to soar. 
Via The Motley Fool
NVAX Stock: The Big Reason Why Novavax Shares Are Gaining Today
A Japanese pharma giant has partnered with Novavax to supply millions of vaccines. NVAX stock is reacting accordingly. 
Via InvestorPlace
Novavax Shares Surge On Vaccine Supply Deal With Japan
Novavax, Inc. shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. 
Via Talk Markets
Novavax Shares Surge On Vaccine Supply Deal With Japan
Novavax, Inc. (NASDAQ: NVAX) shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. What Happened: Japanese pharma giant Takeda... 
Via Benzinga
Mu - The Newest Worry
Today London and New York fell on the huge drop in new employment levels in August. 
Via Talk Markets
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna Reviews Contamination In Vaccine Lot Distributed In Japan
Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of... 
Via Benzinga
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma
New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ)... 
Via Benzinga
Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know
After receiving reports on more contaminated vials and two deaths, Japan has suspended another million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19... 
Via Benzinga
Topics Death
Suspected Metallic Particles Behind Moderna's Japan COVID-19 Jab Contamination: Reuters
Metallic particle is believed to be a contaminant found in a batch of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines delivered to Japan, Japanese public broadcaster... 
Via Benzinga
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received... 
Via Benzinga
Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns
More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia... 
Via Benzinga
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
From Takeda Pharmaceutical Company Limited
Via Business Wire
Friday the Thirteenth
The stock week in points eastward was mixed. The USA markets face a bear correction. 
Via Talk Markets
Takeda To Lead Finch-Partnered Microbiome IBD Drug
Finch Therapeutics Group Inc (NASDAQ: FNCH) announced that Takeda Pharmaceutical Company Limited (NYSE: TAK) has elected to take the lead on the development of FIN... 
Via Benzinga
Why BioCryst Pharmaceuticals Rose 8% on Thursday
The company's first commercial drug launch keeps exceeding expectations. 
Via The Motley Fool
Topics Earnings
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
From Takeda Pharmaceutical Company Limited
Via Business Wire
Know When To Hold 'Em, Know When To Fold 'Em ...
A long Monday list identifying some sensible and some impenetrable moves behind today's market in our stocks. 
Via Talk Markets
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.